The most common side effects of Tremfya for psoriatic arthritis are infection, headaches, skin reactions where the needle went in, joint pain, and diarrhea. Tremfya increases your risk of ...

Tremfya is the first and only fully-human, dual-acting IL-23p19 subunit inhibitor approved in both ulcerative colitis and ...

Tremfya is an interleukin-23 inhibitor being evaluated for the treatment of psoriatic arthritis. Twenty-four-week results showed Tremfya reduced signs, symptoms and structural progression of the ...

While Tremfya is seen as a follow-up to Stelara psoriatic arthritis is becoming a highly crowded market, where Novartis’ IL-17 inhibitor Cosentyx (secukinumab) is becoming well established.

Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis BARCELONA, June 11 ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.

Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis ...